American Cancer Society Updates Prostate Cancer Screening Guidelines to Recommend Routine PSA Testing
Clinical Summary:
- Guideline Update: The American Cancer Society updated its prostate cancer screening guidelines to recommend regular PSA-based testing, replacing its previous approach that primarily emphasized shared decision-making without directly recommending routine screening.
- Key Recommendations: Biennial PSA screening is recommended for average-risk patients aged 50 to 69 years, with annual screening beginning at age 45 for Black patients and non-Black patients with a strong family history of prostate cancer. The guidelines also address elevated PSA thresholds, secondary testing, and screening decisions in older adults.
- Clinical Relevance: These recommendations aim to improve early detection of clinically significant prostate cancer and reduce prostate cancer mortality while minimizing unnecessary biopsies and treatment through confirmatory testing, individualized decision-making, and active surveillance.
The American Cancer Society has updated its prostate cancer screening guidelines to recommend regular prostate-specific antigen (PSA)-based testing for patients at average and elevated risk, introducing biennial screening for average-risk patients and earlier annual screening for Black patients and those with a strong family history of prostate cancer.
These updated recommendations were released on November 12, 2026, and published simultaneously in CA: A Cancer Journal for Clinicians. The guidelines replace the American Cancer Society’s 2010 guidance, which emphasized shared decision-making rather than directly recommending regular PSA-based screening.
The guideline recommends PSA-based screening every 2 years for average-risk patients aged 50 to 69 years, with clinicians ensuring patients understand the potential benefits, limitations, and harms before initiating testing.
For patients at higher risk, including Black patients and non-Black patients with a strong family history of prostate cancer, annual PSA-based screening is recommended beginning at age 45 and continuing through age 69.
A strong family history is defined as having a first-degree relative diagnosed with prostate cancer before age 65 or multiple first-degree relatives diagnosed at any age. For non-Black patients with a single first-degree relative diagnosed at age 65 or older, the guideline recommends PSA-based screening every 2 years from ages 45 to 69.
For patients aged 70 to 74 years, continued screening should be individualized because the balance of potential benefits and harms remains uncertain. The guideline does not recommend routine screening for patients aged 75 years and older, although some very healthy patients aged 75 to 79 years may consider continued screening following discussion with their healthcare provider, particularly if PSA levels have been increasing. Screening is not recommended for patients aged 80 years or older or those with a life expectancy of less than 10 years.
The updated guidance also provides recommendations for evaluating elevated PSA levels to reduce unnecessary biopsies and overtreatment. Men aged 45 to 69 years with PSA levels of at least 3.0 ng/mL and aged 70 to 74 years with PSA levels of at least 6.5 ng/mL should undergo repeat PSA testing within 2 weeks to 3 months.
For patients with confirmed elevated PSA levels, the guidance recommends offering magnetic resonance imaging (MRI) and/or validated biomarker testing to guide decisions regarding prostate biopsy. Patients diagnosed with prostate cancer at low risk of progression should be offered active surveillance as the initial management approach.
The updated recommendations reflect stronger evidence supporting PSA-based screening to reduce prostate cancer mortality and the incidence of advanced-stage disease, alongside advances in diagnostic and management strategies intended to limit unnecessary interventions.
The guideline was developed following a systematic evidence review and a commissioned modeling study evaluating the benefits and harms of different PSA-based screening strategies. An interdisciplinary guideline development group, including clinicians, epidemiologists, biostatisticians, and patient representatives, reviewed the evidence and developed the updated recommendations.
The updated guidelines also emphasize addressing disparities in prostate cancer outcomes. According to the American Cancer Society, Black patients experience a 67% higher incidence of prostate cancer and nearly twice the mortality rate compared with White patients, supporting the recommendation for earlier and more frequent screening in this population.
The guidelines underscore the importance of informed decision-making, risk-based screening, and appropriate follow-up testing to identify clinically significant prostate cancer while minimizing the harms associated with overdiagnosis and overtreatment.
The American Cancer Society concluded that regular PSA-based screening, combined with advances in secondary testing and active surveillance, may improve early detection and reduce prostate cancer mortality while limiting unnecessary diagnostic procedures and treatment.
Source:
PRNewswire. American Cancer Society updates prostate cancer screening guideline: Major changes include regular PSA testing for average and high-risk men. Accessed on: November 12, 2026. https://www.prnewswire.com/news-releases/american-cancer-society-updates-prostate-cancer-screening-guideline-major-changes-include-regular-psa-testing-for-average-and-high-risk-men-302937363.html


